Antihemophilic Factor (Recombinant) (Bioclate (Armour), Recombinate)
Antihemophilic Factor (Recombinant) is an FDA-licensed reference biologic from Takeda Pharmaceuticals U.S.A., Inc.. Reference exclusivity, biosimilar lineage, and published patents from official FDA Purple Book records.
0
Biosimilars
0
Interchangeables
0
Listed patents
2010
Reference approved
Reference product
Bioclate (Armour), Recombinate Antihemophilic Factor (Recombinant)
Takeda Pharmaceuticals U.S.A., Inc.
- Approved
- Mar 10, 2010
- Marketing
- Rx
- Center
- CBER
- Patents
- None listed
Exclusivity & patent cliffs
Approval, exclusivity, and published-patent expiration dates for Antihemophilic Factor (Recombinant), in chronological order.
Reference approval
Approval date of the reference Antihemophilic Factor (Recombinant) product.
16 yr 6 mo ago
Frequently asked questions
Are there biosimilars approved for Antihemophilic Factor (Recombinant) (Bioclate (Armour), Recombinate)?
No 351(k) biosimilars or interchangeable biosimilars referencing Antihemophilic Factor (Recombinant) are listed in the FDA Purple Book yet.
Explore the full FDA Purple Book
Search every FDA-licensed biologic, biosimilar, and interchangeable with exclusivity timelines and patent records.